Story thread · 2 reports / 1 sources
Incyte forecasts $5.130B-$5.260B 2026 net sales as Opzelura guidance rises to $1.050B-$1.1B after CMS settlement
seekingalpha.com · 14d
First report: Incyte raises sales outlook as Opzelura, cancer portfolio fuel strong quarter — seekingalpha.com, 14d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.